What is the primary focus of this 10-Q filing?

This 10-Q filing provides a quarterly update on Bristol Myers Squibb's financial performance, operational results, and financial condition for the period ending June 29, 2019. It includes detailed financial statements, management's discussion of results, and disclosures on risk factors and legal proceedings.

Where can I find information about BMY's revenue and profitability?

Information regarding BMY's revenue and profitability can be found in the 'Consolidated Statements of Earnings and Comprehensive Income' and within the 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' sections of the filing.

What are the key risks and legal matters mentioned in the report?

The filing includes a section on 'Risk Factors' (Item 1A) which details potential challenges and uncertainties the company faces. 'Legal Proceedings' (Item 1) outlines any significant ongoing legal matters that could impact the company's financial or operational standing.

Does this filing provide information on the company's cash flow and liquidity?

Yes, the 'Consolidated Statements of Cash Flows' provides details on the company's cash generation and usage, while the 'Consolidated Balance Sheets' and the MD&A section offer insights into the company's liquidity and overall financial health.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2019

Summary

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending June 29, 2019, reporting on its financial performance and operational highlights. The filing indicates continued focus on its core pharmaceutical business, with investments in research and development driving innovation and pipeline expansion. Investors should pay close attention to the company's revenue streams, particularly the performance of key products, and its strategic initiatives aimed at long-term growth and market leadership in the biopharmaceutical sector. The report also details the company's financial position, liquidity, and any significant legal or regulatory matters that could impact future results.

Financial Highlights

57 data points

Beta

Revenue

$6.27B

0.7% Gross Margin

Net Income

$1.43B

0.2% Net Margin

EPS (Diluted)

$0.87

Total Assets

$55.16B

Cash & Equivalents

$28.40B

Free Cash Flow

$1.89B

Financial Statements

Beta

Revenue	$6.27B
Cost of Revenue	$1.97B
Gross Profit	$4.30B
R&D Expenses	$1.32B
SG&A Expenses	$1.08B
Operating Expenses	$4.50B
Interest Expense	$123.00M
Net Income	$1.43B
EPS (Basic)	$0.88
EPS (Diluted)	$0.87
Shares Outstanding (Basic)	1.64B
Shares Outstanding (Diluted)	1.64B

Key Highlights

1The report covers the financial performance for the quarter ended June 29, 2019, providing an update on BMY's operational and financial standing.
2Key financial statements including Consolidated Statements of Earnings, Comprehensive Income, Balance Sheets, and Cash Flows are presented.
3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition, results of operations, and market risk.
4The filing includes disclosures on legal proceedings and risk factors, which are crucial for understanding potential challenges and uncertainties.
5Information regarding unregistered sales of equity securities and the use of proceeds, if any, is also provided.
6Exhibits are listed, which may contain important supporting documentation for the financial data and operational details.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions